Skye Bioscience Inc. (SKYE) 12-Month Stock Forecast & Price Target Cone

The Roarable RQD rating assigns SKYE a score of 35 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow," per the Roarable RQD rating.

Across the five pillars:

• Fundamental Cash Engine: 8 / 20. The pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is currently consuming capital rather than generating a return on it. The absence of positive cash generation removes the usual valuation anchor, so the share price rests on expectations of future outcomes that the source data does not quantify.
• Whale 13F Flow: 3 / 20. The pillar captures institutional accumulation and options positioning, and it scores near the bottom of its range. The source data contains no holder detail (see the Analyst View section), so the low score signals weak or absent institutional sponsorship rather than a specific selling event.
• Insider Conviction: 5 / 20. The pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score here means the source data does not show insider activity that would indicate management confidence in the shares.
• Macro Regime Fit: 9 / 20. The pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 indicates market-level volatility in the source data, but the score is held down by the company's sector exposure and its lack of revenue.
• Forensic Balance Sheet: 10 / 20. The pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski reading of 2/9 is weak, and the balance sheet data shows cash declining from $68.4M to $5.9M across the reported fiscal years.

Taken together, the pillars describe a company with a weak cash-generation profile, limited institutional and insider support in the source data, and a balance sheet under visible strain. The score suggests that a prospective investor evaluating SKYE today would be weighing a highly speculative equity against a shrinking cash position. Upside would depend on developments outside the reported financials, which the source data does not describe. The valuation tradeoff is stark: with no earnings, no revenue, and negative ROIC, conventional multiples are unavailable, leaving price as the only observable signal.

Skye Bioscience Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model. The FY 2025 and FY 2024 financials report revenue of $0.0M in each year, so the source data shows no reported revenue in the periods covered.

Per the SEC financials, the company reported operating losses in all three periods, with the FY 2025 operating loss of $-58.2M the largest in the table. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating's forensic balance sheet pillar. Reported cash fell from $68.4M in FY 2024 to $5.9M in FY 2025, and debt is listed as N/A in the reported periods.

The news feed contains six items, all rated YELLOW and labeled MARKET WIRE:

• StockInvest.us published a stock price forecast and buy-or-sell commentary on SKYE.
• Moomoo published a stock forum and discussion item.
• Stock Titan reported that two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares.
• TradingView published an item titled around the SKYE Q3'26 earnings with a revenue estimate of 0 USD.
• Yahoo! Finance Canada published a seasonal returns chart for Kazia Therapeutics Limited (KZIA), a different issuer.
• TradingKey published a most-active-stocks item covering the U.S. market.

Risk watch items from the feed are the reported shared voting power over 263,560 shares, and the 0 USD revenue estimate attached to the upcoming quarter. The KZIA item is unrelated to SKYE and carries no company-specific information. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated counterparties for SKYE. Sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) are the only sector-level context available. An investor looking for second-order ripples should note that the source data does not map any dependencies, and any such analysis would require information not contained in this dataset.

• What products or development programs does the company have, and what regulatory milestones are tied to them? The source data does not describe the business beyond its sector classification.
• What is the source of the reported decline in cash from $68.4M to $5.9M, and what is the company's runway at the FY 2025 burn rate of $-43.1M in free cash flow?
• What is the debt position? The debt line is N/A across all reported periods, and the Debt/Equity ratio of 0.5 cannot be traced to its components in the source data.
• Who are the two holders reporting shared voting power over 263,560 shares, and what is the nature of that arrangement?
• What explains the 52-week price range of $1.25 to $12.96, and what drove the -13.82% change in the most recent session?